September 21st 2024
Pembrolizumab led to improved survival over ipilimumab in patients with unresectable advanced melanoma, according to long-term data.
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma
September 18th 2022The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable Melanoma
September 13th 2022The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
July 13th 2022Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
FDA Follow-Up: Utilizing Relatlimab/Nivolumab in Clinical Practice for Metastatic Melanoma
March 25th 2022Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.
FDA Follow-Up: Utilizing Tebentafusp in Clinical Practice for Metastatic Uveal Melanoma
February 4th 2022Oncology Nursing News® meets with the lead investigator behind the phase 3 IMCgp100-202 trial to better understand the significance of tebentafusp’s approval and to determine what oncology nurses need to know about the new agent.
Pembrolizumab May Be Associated with Sustainable Relapse-Free Survival in High-Risk Melanoma
November 8th 2021After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.